Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Rheumatoid Arthritis: Update Bulletin [December 2014]

Product Code:
596200332
Release Date:
December 2014
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Rheumatoid Arthritis: American College of Rheumatology (ACR) Annual Meeting data on secukinumab in psoriatic arthritis and ankylosing spondylitis;phase IIb data for mavrilimumab; Orencia (abatacept) subset data from AVERT study;Prime Therapeutics' FPA 008 and Protalex's PRTX 100; RA-MOBILITY secondary endpoint data.

Highlights from this event update bulletin

  • Will positive psoriatic arthritis and ankylosing spondylitis phase III data for secukinumab have any bearing on its development for RA?
  • How do KOLs view mavrilimumab?
  • Will abatacept’s (Orencia) usage change in the future?
  • How are new early-stage products, FPA 008 and PRTX 100 perceived by KOLs?
  • How important are the secondary endpoint results from sarilumab’s RA-MOBILITY trial?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved